Home>Topics>Authors>Damien Conover

Damien Conover

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

    Video Reports

    Thu, 21 May 2015

    Coffina. I am joined today by Damien Conover , who is the director of our health ..... Damien, thanks for joining me. Damien Conover : Matt, thanks for having me ..... Great. Thanks for joining me, Damien . Conover : Matt, thanks for having me

    Damien Conover found at 0:06, 4:30

    For Morningstar StockInvestor , I'm Matt Coffina. I am joined today by Damien Conover , who is the director of our health-care team. We are going to talk about immuno-oncology drugs. Damien, thanks for joining me. Damien Conover : Matt, thanks for having me. Coffina: So, immuno-oncology is a really hot topic in pharma right now. What exactly are these drugs?
    as those other three companies have. Coffina: Great. Thanks for joining me, Damien . Conover : Matt, thanks for having me. Coffina: So, in conclusion, we think immuno-oncology is a particularly promising area for growth for pharmaceutical firms
  2. Ultimate Stock-Pickers’ Top 10 High-Conviction and New-Money Purchases

    Headlines

    Tue, 19 May 2015

    will be partially tempered by patent exposures in the company’s pharmaceutical franchises. Morningstar analyst Damien Conover notes that Johnson & Johnson stands alone as a leader across the major health-care industries. He sees the company

  3. Market Undervalues Merck’s Pipeline

    Headlines

    Tue, 28 Apr 2015

    New products will secure the drug firm’s wide moat and help increase the firm’s valuation over time, writes Morningstar’s Damien Conover .

  4. Friday Five: Banks Start Earnings Season Without a Bang

    Video Reports

    Thu, 16 Apr 2015

    Johnson also reported. They had a steady quarter, but not perhaps without any bumps at all. Glaser: Our analyst Damien Conover described it as steady. It was driven by the drug business; pharmaceuticals are really driving [TICKER:JNJ

    Damien Conover found at 1:39

    quarter, but not perhaps without any bumps at all. Glaser: Our analyst Damien Conover described it as steady. It was driven by the drug business; pharmaceuticals are really driving [TICKER:JNJ] Johnson & Johnson's performance. The consumer group
  5. Friday Five: What Will the Fed Do Now?

    Video Reports

    Fri, 6 Feb 2015

    paying a pretty decent premium to acquire [TICKER:HSP] Hospira (HSP). What's our take on that deal? Glaser: Damien Conover , our Pfizer analyst, thinks that it's going to be a good one for the pharmaceutical giant. They're spending

    Damien Conover found at 3:30

    premium to acquire [TICKER:HSP] Hospira (HSP). What's our take on that deal? Glaser: Damien Conover , our Pfizer analyst, thinks that it's going to be a good one for the pharmaceutical giant. They're spending $16 billion for the
  6. Obama Pushes to Overhaul Silly, Counterproductive U.S. Corporate Tax System

    Headlines

    Wed, 4 Feb 2015

    portfolio adjustments in anticipation of it. Morningstar's director of healthcare equity research and equity strategy, Damien Conover , who covers a number of pharmaceutical firms that use sophisticated tax-management strategies, said that Obama

  7. J&J Faces Headwinds in 2015

    Headlines

    Tue, 20 Jan 2015

    The pharmaceutical giant turned in an in line fourth-quarter, but new competition and a strong dollar will slow growth in 2015, writes Morningstar’s Damien Conover .

  8. From Fear of an Overheating U.S. Economy to Doom and Gloom in One Easy Week

    Headlines

    Sat, 17 Jan 2015

    the long-term trend of higher and higher prices had been broken. According to Morningstar healthcare team leader Damien Conover , a combination of higher prices from the consolidated generics industry, fewer drugs going off patent, and more

  9. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Video Reports

    Fri, 2 Jan 2015

    Coffina. I'm joined today by Damien Conover , who is the director of our health ..... Damien, thanks for joining me. Damien Conover : Matt, thanks for having me ..... Coffina: Thanks for joining me, Damien . Conover : Matt, thanks for having me

    Damien Conover found at 0:06, 3:45

    Coffina: For Morningstar StockInvestor , I'm Matt Coffina. I'm joined today by Damien Conover , who is the director of our health-care team. We are going to talk about pharmaceutical firms' pipelines. Damien, thanks for joining me. Damien Conover : Matt, thanks for having me. Coffina: Every year, you do this analysis using our proprietary box methodology, as we call it, basically
    strikeouts, and that really hurt their pipeline. Coffina: Thanks for joining me, Damien . Conover : Matt, thanks for having me. Coffina: In conclusion, in this year's Big Pharma ranking, Merck and [TICKER:SNY] Sanofi came out on top--Merck because
  10. Friday Five: China's Tricky Gambit for Growth

    Video Reports

    Thu, 11 Dec 2014

    acquiring Cubist. What's our take on the deal? Glaser: Merck is going to spend $9.5 billion for Cubist, and Damien Conover , our health-care analyst, thinks this is about expanding Merck's presence into the hospital acute-care segment

    Damien Conover found at 3:26

    deal? Glaser: Merck is going to spend $9.5 billion for Cubist, and Damien Conover , our health-care analyst, thinks this is about expanding Merck's presence into the hospital acute-care segment, and he thinks that's something that will
« Prev1234Next »
Content Partners